TABLE I.
Model Inputs
| Name | Base Case | Range | Distribution | Source |
|---|---|---|---|---|
| Demographic and test characteristics | ||||
| Prevalence of DNA-positive HBV detected at Screening | 0.0023 | (0.0018–0.0028) | Uniform | Current study |
| Surface antigen sensitivity | 1.0 | (1.0–1.0) | Uniform | BIO-RAD GS HBsAg EIA 3.0 |
| Surface antigen specificity | 0.998 | (0.9973–0.9987) | Uniform | BIO-RAD GS HBsAg EIA 3.0 |
| Surface antibody sensitivity | 0.9926 | (0.9852–1.0) | Uniform | BIO-RAD MONOLISA Anti-HBs EIA |
| Surface antibody specificity | 0.963 | (0.962–0.964) | Uniform | BIO-RAD MONOLISA Anti-HBs EIA |
| Enter asymptomatic carrier | 0.35 | (0.25–0.45) | Uniform | Eckman et al.19 |
| Stay 5 yr in service | 0.83 | (0.71–0.97) | Normal | Defense Business Board18 |
| Probability that a recruited service member passes medical screening and boot camp and proceeds to military service | 0.71 | (0.71–0.71) | Uniform | AMSARA17 |
| Detectable HBV immunity | 0.4 | (0.3–0.5) | Uniform | Susan Varner, personal communication |
| Probability of being foreign-born | 0.077 | (0.052–0.102) | Uniform | Current study |
| Prevalence of HBV infection in foreign-born | 0.0128 | (0.0078–0.0178) | Uniform | Current study |
| Markov model HBV disease progression probabilities | ||||
| Progression through stages of HBV infection (stratified by HBV DNA levels < 2 k, 2–20 k, and > 20 k) from immunotolerant through chronic infection, cirrhosis, hepatocellular carcinoma, liver transplant, and death using previously published estimates of disease state transition probabilities | Eckman et al.19 | |||
DNA, deoxyribonucleic acid; HBV, hepatitis B virus; AMSARA, Accession Medical Standards Analysis and Research Activity.